Provided by Tiger Trade Technology Pte. Ltd.

Minerva Neurosciences

5.21
-0.2900-5.27%
Post-market: 5.210.00000.00%16:25 EDT
Volume:90.32K
Turnover:474.08K
Market Cap:242.73M
PE:-0.18
High:5.53
Open:5.43
Low:5.16
Close:5.50
52wk High:12.46
52wk Low:1.30
Shares:46.59M
Float Shares:27.93M
Volume Ratio:0.71
T/O Rate:0.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-29.0966
EPS(LYR):-34.6700
ROE:-675.09%
ROA:-27.47%
PB:-0.96
PE(LYR):-0.15

Loading ...

Minerva Neurosciences Launches Key Phase 3 Test for Roluperidone in Schizophrenia

TIPRANKS
·
Yesterday

Minerva Neurosciences Q1 Adj. EPS $(0.17) Misses $(0.13) Estimate

Benzinga
·
May 05

Minerva Neurosciences Q1 net loss widens to $125.4 million

Reuters
·
May 05

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

GlobeNewswire
·
May 05

Minerva Neurosciences files Form 3 for Chief Business Officer and GC James Joseph O'Connor

Reuters
·
Apr 23

Minerva Neurosciences Initiated at Market Outperform by Citizens

Dow Jones
·
Apr 15

Minerva initiated with an Outperform at Citizens

TIPRANKS
·
Apr 15

Minerva Neurosciences announces upcoming annual shareholder meeting

Reuters
·
Apr 07

Minerva Neurosciences Appoints New Chief Business Officer, Counsel

TIPRANKS
·
Apr 03

Minerva appoints Jim O'Connor chief business officer as President Geoff Race exits

Reuters
·
Apr 03

Press Release: Minerva Announces Leadership Transition

Dow Jones
·
Apr 03

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

GlobeNewswire
·
Apr 01

Minerva Neurosciences presents open-label safety trial data; roluperidone-olanzapine co-administration shows no safety concerns at SIRS 2026

Reuters
·
Mar 26

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Minerva Neurosciences (NERV)

TIPRANKS
·
Mar 16

Minerva Neurosciences Is Maintained at Neutral by HC Wainwright & Co.

Dow Jones
·
Mar 12

Minerva Neurosciences to Present at Stifel Virtual CNS Forum

Reuters
·
Mar 12

U.S. RESEARCH ROUNDUP-AeroVironment, Bumble, Lumentum.

Reuters
·
Mar 12

Minerva Neurosciences Warns of Major Dilution Risk From Preferred Stock Conversions and Warrant Exercises

TIPRANKS
·
Mar 12

Minerva Neurosciences Inc - May Offer up to $200 Mln of Securities in Multiple Offerings - SEC Filing

THOMSON REUTERS
·
Mar 11

Minerva Neurosciences Q4 Adj. EPS $(0.64) Misses $(0.30) Estimate

Benzinga
·
Mar 11